⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2024Dermatology and TherapyOpen Access

Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

Rui Sun Mercedes Bustamante Venkatesh Kumar Gurusamy Mark Lebwohl Alice B. Gottlieb Philip J. Mease Atul Deodhar Weibin Bao Meryl H. Mendelson Brian Porter Deepa H. Chand Victor Dong

View Full Paper

Ask AI

Bookmark

Share

Abstract

Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 June 2022.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sun et al. (2024) studied this question.

synapsesocial.com/papers/68e761d0b6db6435876d81b4 https://doi.org/10.1007/s13555-024-01122-2

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy, Safety, and Tolerability of Secukinumab in Psoriatic Arthritis: A Systematic Review and Meta-AnalysisHuman Clinical Trial · 2026
2Efficacy and safety of secukinumab in psoriasis: five-year real life experience2024 · 1 citations
3Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective StudyCohort Study · 2026 · 1 citations
4Secukinumab: A Breakthrough in the Treatment of Autoimmune Disease2024
5Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in KoreaOriginal Research · 2024 · 5 citations